Malignant changes in the prostate with ageing

British Journal of Urology

Volumn 82, Issue SUPPL. 1, 1998, Pages 47-58

  Dunsmuir, W D ^a   Hroiida, D ^b   Kirby, R S ^a,b  

^a ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Age; Apoptosis; Cell cycle; Malignancy; Mortality; Prostate; Senescence

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

APOPTOSIS; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CELL CYCLE; CELL DAMAGE; DIAGNOSTIC ACCURACY; ETHNIC DIFFERENCE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SENESCENCE; TRANSURETHRAL RESECTION; TUMOR SUPPRESSOR GENE;

AGED; AGED, 80 AND OVER; AGING; APOPTOSIS; CELL CYCLE; HUMANS; IMMUNITY; MALE; PROSTATIC NEOPLASMS; WORLD HEALTH;

EID: 0031762514     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1998.0820s1047.x     Document Type: Article

References (132)

1. Thompson H. Cancer of the prostate. In Diseases of the Prostate: their Pathology and Treatment, 3rd edn, Chapt XIV 1862: 263
2. Diczfalusy E. An aging humankind: is our future behind us? Aging Male 1998: 1: 8-19
3. World Health Organisation Division of Health Promotion Education and Communication Health of the Elderly Unit/HEEJ. Report of the 95th Executive Board. Document WHO/HPR/HEE/95 1. World Health Organisation 1995
4. World Health Organisation. Epidemiology and Prevention
5. of Cardiovascular Diseases in Elderly People. WHO Technical Report Series No 853. 1995
6. Office of Population Censuses & Surveys. Mortality Statistics: cause. 1993 (revised) and 1994. Series DH2 no. 21. London: HMSO 1996
7. Chamberlain J, Melia J. Moss S. Brown J. Report prepared for the health technology assessment panel of the NHS executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales. Br J Urol 1997: 79 (suppl 3): 1-32
8. Stephenson RA. Smart CR. Mineau GP. James BC. Janerich DT. Dibble RL. The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence-data from the Utah Cancer Registry. Cancer 1996; 77: 1342-8
9. Boyle P. Maisonneuve P. Napalkov P. Prostate Cancer: The Treat to Health and Strategies for Control. In Peeling WB. ed. Questions and Uncertainties about Prostate Cancer, Chapt 1. London: Blackwell Science. 1996: 3-29
10. Ndubuisi SC, Kolie VY. Andoh JY. Schwartz EM. Black-white differences in the stage at presentation of prostate cancer in the District of Columbia. Urology 1995; 46: 71-7
11. Mebane C. Gibbs T. Horm J. Current status of prostate cancer in north American black males. J Natl Med Assoc 1990: 82: 782-8
12. Sakr WA. Grignon DJ. Haas GP. Heilbrun LK. Pontes JE. Crissman JD. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 1996: 30: 1 38-44
13. Baron E. Angrist A. Incidence of occult adenocarcinoma of the prostate after fifty years of age. Arch Palhol 1941: 32: 787-93
14. Edwards CN. Steinthosson E. Nicholson D. An autopsy study of latent prostatic cancer. Cancer 1953; 6: 531-54
15. Franks LM. Durg MB. Latent carcinoma of the prostate. J Clin Path 1954; 68: 603-16
16. Viitanen I. Hellens A. Latent carcinoma of the prostate in Finland. Acta Pathol Microbiol Scant! 1958: 44: 64-7
17. Karube K. Study of latent carcinoma in the Japanese based on necropsy material. Tohciku J Exp Med 1961; 74: 265-85
18. Halpert B. Sheehan E. Schmalhorst W. Scott R. Carcinoma of the prostate: a survey of 5000 autopsies. Cancer 1998: 82: 737-42
19. Liavag I. Atrophy and regeneration in the pathogenesis of prostatic carcinoma. Acta Pathol Microbiol Scand 1968: 73: 338-50
20. Lundberg S. Berge T. Prostate carcinoma: an autopsy study. Scand J Urol Nephrol 1970: 4: 93-7
21. Harbits T. Haugen OA. Histology of the prostate in elderly men. Acta Pathol Microbiol Scand 1972; 80: 756-68
22. Akazaki K. Stemmermann J. Comparative study of latent carcinoma of the prostate among Japanese in Japan and Hawaii. J Natl Cancer hist 1973: 50: 1137-44
23. Breslow N. Chan CW. Dhom G. Latent carcinoma of prostate in seven areas, Int J Cower 1977: 20: 680-8
24. Holund B. Latent prostatic cancer in a consecutive autopsy series. Scand J Ural Nephrol 1980; 14: 29-35
25. Guileyardo J. Johnson W. Welsh R. Akakazi K, Correa P. Prevalence of latent prostatic carcinoma in two U.S. populations. J Natl Cancer Inst 1980: 65: 311-6
26. Yatani R, Chigusa I. Akazaki K. Stemmermann GN. Welsh RA. Geographic pathology of latent prostatic carcinoma. Int l Cancer 1982: 29: 611-6
27. Dhom G. Epidemiologie aspects of latent and clinically manifest carcinoma of the prostate. J Cancer Res Clin Oncol 1983: 106: 210-8
28. Mettlin C. Jones GW. Murphy GP. Trends in prostate cancer care in the United States. 1974-90: observations from the patient care evaluation studies of the American College of Surgeons commission on cancer. CA Cancer J Clin 1995: 43: 83-91
29. Yatani R. Shiraishi T. Nakakuki K et al. Trends in frequency of latent prostate carcinoma in Japan from 1965-1979 to 1982-1986. J Natl Cancer lust 1988: 80: 683-7
30. George NJ. Incidence of prostate cancer will double by the year 2030: the argument against, Eur Urol 1996: 29: 10-2
31. Tretli S. Engeland A. Haldorsen T et ni. Prostate cancer look to Denmark? J Natl Cancer lust 1996: 88: 128
32. Brawley OW. Kramer BS. Epidemiology of prostate cancer. In Vogelzang NJ. Scardino PT. Shipley WU. Cofl'ey DS. eds. Comprehensive Textbook of Genitourinary Oncolotiij. Chapt 33. Philadelphia: Williams & Watkins. 1996: 565-72
33. Clive JM. Spencer RP. Analysis of mortality rate from carcinoma of prostate, Mechan Aaeinij Devel 1995; 83: 51-41
34. Mettlin CJ. Murphy GP. Why is the prostate cancer death rate declining in the United States? Cancer 1998: 82: 249-51
35. Garraway WM, Alexander EE. Prostate disease: epidemiology, natural history and demographic shifts. Br J Urol 1997: 79: 5-8
36. Balducci L. Lyman GH. Cancer in the elderly. Epidemiologic and clinical implications. Clin Ger Med 1997: 13: 1-14
37. Office of Population Censuses & Surveys. Mortality statistics: cause 1984. London: HMSO 1985
38. Parkes CA. An epidemiologist's viewpoint on screening. Cancer Snrv 1995; 23: 127-40
39. Office of Population Censuses & Surveys. Morbidity Statistics from General Practice. Fourth National Study 1991-92. Series MB5. London: HMSO 1995
40. Hunter DJ. McKee CM. Black NA. Sanderson CE. Health care sought and received by men with urinary symptoms, and their views on prostatectomy. Br J Gen Pract 1995: 45: 27-50
41. Kirby RS. Chisholm C,. Chappie C. Hudd C. Swallow M. Shore 1). Shared care between general practitioners and urologists in the management of benign prostatic hyperplasia: a survey of attitudes among clinicians. J R Soc Med 1995: 88: 284-8
42. Fawzy A. Fontenot C. Guthrie R. Baudier MM. Practice patterns among primary care physicians in benign prostatic hyperplasia and prostate cancer. Fam Med 1997: 29: 521-5
43. Office of Health Economics. Compendium of Health Statistics. 9th edn. London 1995
44. Department of Health. Hospital Episode Statistics Vol. I. Finished Consultant Episodes by Diagnosis. Operation and Speciality. England: Financial Year 1993-94. London: HMSO 1995
45. Department of Health & Social Security. 1985 Hospital in-patient Enquiry. Summary tables. England. 1987
46. Kirkvvood TLB. Evolution of aging. \atnre 1977: 270: 301-4
47. Banks DA. Fossel VI. Telomeres. cancer and aging. Altering the human life span. JAMA 1997: 278: 1345-8
48. Campisi J. Aging and cancer: the double-edged sword of replicative senescence. J Am Ger S'cc 1997: 45: 482-8
49. Shay JW. Telomerase in human development and cancer. J Cell Physiol 1997: 173: 266-70
50. Zhang W. Kapusta LR. Slingerland JM. Klotz LH. Telomerase activity in prostate cancer, prostatic intraepithclial neoplasia, and benign prostatic epithelium. Cancer Res 1998; 58: 019-21
51. Kallakury BV. Brien TP. Lowry CV et al. Telomerase activity in human benign prostate tissue and prostatic adenocarcinomas. Diaij Mol Pathol 1997: 6: 192-8
52. Scales DK. Vluir GIL Venitt S. Carmichael PL. Detection of telomerase activity in human prostate: a diagnostic marker for prostatic cancer? Br J Urol 1997: 80: 263-8
53. Takahashi C. Miyagawa I. Kumano S. Oshimura M. Detection of telomerase activity in prostate cancer by needle biopsy. Eur Urol 1997: 32: 494-8
54. Lin Y. llemura H. Fujinami K. Hosaka M. Harada M. Kuhota Y. Telomerase activity in primary prostate cancer. J Urol 1997: 157: 1 161-5
55. Sommerfeld HJ. Meeker AK. I'iatysxek MA. Bova US. Shay JW. C'offey DS. Telomerase activity: a prevalent marker of malignant human prostate tissue. Cimcer K ex 1996: 56: 218-22
56. Sharma S. Raymond E. Soda H cl al. Preclinical and clinical strategies for development of telomerase and telomere inhibitors. /\im Oncol 1997: 8: 1065-74
57. Denmeade SR. Isaacs JT. Prostate cancer: where are we and where are we going.- tir j Urol 1997: 79 (suppl 11: 2-7
58. Cotton DW. Rogers S. Ageing, cancer and mitochondrial deterioration. Lancet 199): 341: 281-2
59. Liu Y. Franklin R15. Costello LC. Prolactin and testosterone regulation of mitochondria! xinc in prostate epithelial cells. Prostate 1997: 10: 26-32
60. Costello LC. Liu Y. Franklin RB. Kennedy MC. Zinc inhibition of mitochondrial aconitase and its importance in citrate metabolism of prostate epithelial cells. JRiol Chem 1997: 272: 28875-81
61. Ripple MO. Henry U'F. Rago RP. Wilding G. Prooxidantantioxidant shift induced by androgen treatment of human prostate carcinoma cells. J\(JCancer lust 1997: 89: 40-8
62. Itoh N. Kakehi Y. Akao T. Kinoshita H. Okada Y. Yoshida O. Concomitant presence of plh/cyclin-dependent kinase 4 and cyclin d/cyclin-dependent kinase 4 complexes in LNcap prostatic cancer cell line. Ipn JCancer Res 1997: 88: 229-33
63. Kubota Y. Fujinami K. Uemura H cl al. Retinoblastoma gene mutations in primary human prostate cancer. Prostate 1995: 27: 314-20
64. Phillips SM, Barton CM, Lee SJ et al. Loss of the retinoblastoma susceptibility gene (rb1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 1994; 70: 1252-7
65. Dahiya R, Deng G, Chen KM, Chui RM, Haughney PC, Narayan P. P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer. Br J Cancer 1996; 74: 264-8
66. Heidenberg HB, Sesterhenn IA. Gaddipati JP et al. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J Urol 1995; 154: 414-21
67. Kubota Y, Shuin T. Uemura H et al. Tumor suppressor gene p53 mutations in human prostate cancer. Prostate 1995; 27: 18-24
68. Gumerlock PH, Chi SG, Shi XB et al. P53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA - the cooperative prostate network. J Natl Cancer Inst 1997: 89: 66-71
69. Theodorescu D, Broder SR. Boyd JC. Mills SE. Frierson HF Jr. P53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 1997: 158: 131-7
70. Shurbaji MS, Kalbfleisch JH. Thurmond TS. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol 1995: 26: 106-9
71. Thomas DJ. Robinson M. King P et al. P53 expression and clinical outcome in prostate cancer. Br JUral 1993; 72: 778-81
72. Henke RP, Kruger E. Ayhan N. Hubner D. Hammerer P, Huland H. Immunohistochemical detection of p53 protein in human prostatic cancer. J Urol 1994; 152: 1297-301
73. Mottaz AE, Markwalder R, Fey MF et al. Abnormal p53 expression is rare in clinically localized human prostate cancer: comparison between immunohistochemical and molecular detection of p53 mutations. Prostate 1997: 31: 209-15
74. Bushman EC, Nayak RN. Bushman W. Immunohistochemical staining of ras p21: staining in benign and malignant prostate tissue. J Urol 1995; 153: 233-7
75. Sumiya H. Masai M, Akimoto S, Yatani R. Shimazaki J. Histochemical examination of expression of ras p21 protein and r 1881-binding protein in human prostatic cancers. Eur J Cancer 1990: 26: 786-9
76. Byrne RL, Horne CH, Robinson MC et al. The expression of waf-1. p53 and bcl-2 in prostatic adenocarcinoma. Br J Urol 1997: 79: 190-5
77. Gao X, Chen YQ, Wu N et al. Somatic mutations of the wafl/cipl gene in primary prostate cancer. Oncogene 1995; 11: 1395-8
78. Gaddipati JP. McLeod DG, Sesterhenn IA et al. Mutations of the pi6 gene product are rare in prostate cancer. Prostate 1997: 30: 188-94
79. Jarrard DF, Bova GS, Ewing CM et al. Deletional, mutational, and methylation analyses of cdkn2 (p16/mts1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer 1997; 19: 90-6
80. Mangold KA, Takahashi H, Brandigi C et al. P16
81. (cdkn2/mtsl) gene deletions are rare in prostatic carcinomas in the United States and Japan. J Urol 1997; 157: 1117-20
82. Tamimi Y, Bringuier PP. Smit F, van Bokhoven A, Debruyne FM, Schalken JA. PI 6 mutations/deletions are not frequent events in prostate cancer. Br J Cancer 1996: 74: 120-2
83. Gotoh A. Kao C, Ko SC. Hamada K, Liu TJ. Chung LW. Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21 wafl/cipl and p!6cdkn4) in human prostate cancers. J Urol 1997; 158: 636-41
84. Kallakury BV. Sheehan CE. Ambros RA. Fisher HA. Kaufman RP Jr, Ross JS. The prognostic significance of p34cdc2 and cyclin dl protein expression in prostate adenocarcinoma. Cancer 1997: 80: 753-63
85. Ershler WB. Longo DL. Aging and cancer: issues of basic and clinical science. JNatl Cancer Inst 1997: 89: 1489-97
86. Hara E, Smith R. Parry D. Tahara H, Stone S, Peters G. Regulation of p16cdkn2 expression and its implications for cell immortalization and senescence. Mot Cell Biol 1996; 16: 859-67
87. Sherr CJ. Roberts JM. Inhibitors of mammalian Gl cyclindependent kinases. Genes Dev 1995; 9: 1149-63
88. Noda A. Ning Y. Venable SF. Pereira-Smith UNM. Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994; 211: 90-8
89. Harley CB. Villeponteau B. Telomeres and telomerase in aging and cancer. Curr Opin Genet Dev 1995; 5: 249-55
90. Wang E. Senescent human fibroblasts resist programmed cell death, and failure to suppress bcl2 is involved. Cancer Res 1995: 55: 2284-92
91. West MD. Pereira-Smith OM, Smith JR. Replicative senescence of human skin fibroblasts correlates with loss of regulation and overexpression of collagenase activity. Exp Cell Res 1989: 184: 138-7
92. Millis AJ. Hoyle M, McCue HM, Martini H. Differential expression of metalloproteinase and tissue inhibitor of metalloproteinase genes in aged human fibroblasts. Exp Cell Res 1992: 201: 373-9
93. Wick M. Burger C, Brusselbach S, Lucibello FC. Muller R. A novel member of human tissue inhibitor of metalloproteinases (TIMP) gene family is regulated during gl progression, mitogenic stimulation, differentiation, and senescence. J Biol Chem 1994; 269: 18953-60
94. Lokeshwar VB. Lokeshwar BL, Pham HT. Block ML. Association of elevated levels of hyaluronidase. a matrixdegrading enzyme, with prostate cancer progression. Cancer Res 1996; 56: 651-7
95. Klein RD. Borchers AH, Sundareshan P et al. Interleukin-lbeta secreted from monocytic cells induces the expression of matrilysin in the prostatic cell line Incap. J Biol Chem 1997: 272: 14188-92
96. Stearns ME, Wang M. Type IV, collagenase (Mr 72.000) expression in human prostate: benign and malignant tissue. Cancer Res 1993; 53: 878-83
97. Pajouh MS. Nagle NB, Breathnach R, Finch JS, Brawer MK. Bowden GT. Expression of metalloproteinase genes in human prostate cancer. JCancer Res Clin Oncol 1991: 117: 144-50
98. Powell WC. Knox JD. Navre M et al. Expression of the metalloproteinase matrilysin in DU-14 S cells increases their invasive potential in severe combined immunodeticient mice. Cancer Res 1993: 53: 417-22
99. Quax PH. de Bart AC. Schalken JA. Verheijen JH. Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: correlation with metastatic behavior in vivo. Prostate 1997: 32: 196-204
100. Wood M, Fudge K. Mohler ]L et al. In situ hybridization studies of metalloproteinases 2 and 9 and T1MP-1 and T1MP-2 expression in human prostate cancer. (7m l-'.xp Metastasis 1997: 15: 246-58
101. Jung K. Nowak L. Lein M. Priem F, Schnorr D. Loening SA. Matrix metalloproteinases l and 3. tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer. Int JCunci-r 1997: 74: 220-3
102. Maier JA. Voulalas P. Roedcr D. Maciag T. Extension of the life-span of human endothelial cells by an interleukin-1 alpha antisensc oligomer. Science 1990: 249: 1570-4
103. Kabalin JN. McNeal JE. Price HM. Ereiha FS. Stamey TA. Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: incidence, histology and morphometric observations. JL'rol 19S9: 141: 1091-4
104. Dimri GP, Lee X. Basile G cl al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Xatl Acad Sei USA 1995: 92: 9363-7
105. Tenniswood M. Apoptosis. tumour invasion and prostate cancer. Br ] Vrol 1997; 79 (Suppl 2): 27-34
106. Hsing AW. Comstock GW. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev 1993; 2: 27-32
107. Nomura A. Heilbrun LK. Stemmermann CN. Judd HI.. Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res 1988: 48: 3515-7
108. Gann PH. Hennekens CH. Ma J. Longcope C. Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J.\'iifJCancer Inst 1996; 88: 1118-26
109. Gray A. Feldman HA. McKinlay JB. Longcope C. Age. disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. JClin Endocrinol Metab 1991: 73: 1016-25
110. Kaufman JM. Giri M. Deslypere JM. Thomas G, Vermeulen A. Influence of age on the responsiveness of the gonadotrophs to luteinizing hormone-releasing hormone in males. JC//H Endocrinol Metab 1991; 72: 1255-60
111. Vermeulen A. Kaufman JM. Ageing of the hypothalamopituitary-testicular axis in men. Hormone Res 1995: 43: 25-8
112. Deslypere JP. Kaufman JM. Vermeulen T. Vogelaers D. Vandalem JL, Vermeulen A. Influence of age on pulsatile luteinizing hormone release and responsiveness of the gonadotrophs to sex hormone feedback in men. JClin Endocrinol Metab 1987; 64: 68-73
113. Carter HB. Pearson JD. Metter EJ et al. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate 1995: 27: 25-31
114. de Jong FH. Oishi K. Rayes RB et ni. Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: results from the DutchJapanese case-control study. Cancer Res 1991: SI: 3445-50
115. Andersson SO. Adami HO. Bergstrom R. Wide L. Serum pituitary and sex steroid hormone levels in the aetiology of prostatic cancer -a population-based case-control study. Kr ] Cancer 1993: 68: 97-102
116. Sanchez-Visconti G. Herrero L. Rabadan M, Pereira I, Ruiz-Torres A. Ageing and prostate: age-related changes in androgen receptors of epithelial cells from benign hypertrophie glands compared with cancer. Median Ayeing Devel 1995: 82: 19-29
117. Miller RA. The aging immune system: primer and prospectus. Science 1996: 275: 70-4
118. Greenberg PD. Adoptive T cell therapy of tumours: mechanisms operative in the recognition and elimination of tumour cells. Adv Immunol 199 1: 49: 281-I55
119. Gillis S. Kozak R. Durante M. Weskler ME. Immunological studies of ageing. Decreased production of and response to T cell growth factor by lymphocytes from aged humans. JClin Invest 1981: 67: 937-42
120. Thoman ML. Weigle WO. Lymphokines and ageing: interleukin-2 production and activity in aged animals. JImnnmol 1981: 127: 2102-6
121. Ershler WB. Sun WH. Binkley N et al. Interleukin-6 and ageing: blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction. Linnphokin Ciftokin Res 1993: 12: 225-30
122. Gittes RF. McCullough DL. Occult carcinoma of the prostate: An oversight of immune surveillance -a working hypothesis. JLi ml 1974: 112: 241-4
123. Vesalainen S. Lipponen P. Talja M. Syranen K. Histological grade, tumour-iniiltrating lymphocytes and apoptosis as determinants of long term prognosis in prostate adenocarcinoma. llw ] Cancer 1994: IOA: 1797-803
124. Blades RA. Renting PJ. McWilliam LJ. George NJ. Stern PL. Loss of Hl.A Class I expression in prostate cancer: implications for immunotherapy. L'ni/o;//; 1995: 46: 687-7
125. Mukheri B. Chakraborty NG. Immunobiology and immunotherapy of melanoma. Curr Opinion Oncul 1995: 7: 175-84
126. Hrouda D. Baban B. Dunsmuir WD. Rirby RS. Dalgleish ACi. Immunotherapy of advanced prostate cancer: a phase I/II trial using mycobacterium vaccae (SRL1 72). Rr ] Ural 1998: 82:
127. Murphy G. Tjoa B. Ragde H. Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1997: 29: 371-80
128. Guinan P. Toronchi E. Shaw M. Crispin R. Shariti R. Bacillus Calmette-Guerin (BCG) adjuvant therapy in stage D prostate cancer. Uroloim 1982: 20: 401-3
129. Prehn RT. The immune reaction as a stimulator of tumour growth. Science 1972: 176: 170-1
130. Ershler WB. Why tumours grow more slowly in older people. JNatl Cancer Inst 1986; 77: 837-9
131. Kanamaru H, Shirahase T. Isogawa Y et al. Clinical and statistical studies on prostate cancer: prognostic value of clinical stage. Gleason score and age. Hinyokika Kiyo 1994: 40: 387-92
132. W.D. Dunsmuir, MBBS. FRCS. Higher Surgical Trainee. Southwest Thames Region. D. Hrouda. MBBS. FRCS. Higher Surgical Trainee. South-west Thames Region. R.S. Kirby. MS, FRCS. Consultant Urological Surgeon and Head of Urological Surgery. Mr R.S. Kirby, Department of Urology. St George's Hospital NHS Trust. Blackshaw Road. Tooting. London, SW1 7 OUT. UK.